MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$3.60
-0.09 (-2.44%)
Open$3.72
Previous Close$3.69
Day High$3.73
Day Low$3.60
52W High$7.99
52W Low$3.03
Volume—
Avg Volume2.14M
Market Cap549.61M
P/E Ratio11.31
EPS$0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+570.8% upside
Current
$3.60
$3.60
Target
$24.15
$24.15
$19.42
$24.15 avg
$35.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 419.87M | 361.77M | 190.63M |
| Net Income | 48.71M | 37.78M | 27.70M |
| Profit Margin | 11.6% | 11.0% | 14.5% |
| EBITDA | 64.93M | 53.15M | 34.17M |
| Free Cash Flow | — | — | 29.04M |
| Rev Growth | +16.1% | +16.1% | +8.9% |
| Debt/Equity | 0.07 | 0.07 | 0.66 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |